Bodey G P, Rodriguez V, Cabanillas F, Freireich E J
Am J Med. 1979 Jan;66(1):74-81. doi: 10.1016/0002-9343(79)90485-6.
Fifty-eight patients with malignant lymphoma were randomly allocated to receive three courses of chemotherapy to induce remission with CHOP-Bleo on the protected environment-prophylactic antibiotic (PEPA) program (30 patients) or as controls (28 patients). The complete remission rate for all patients was 74 per cent, for patients with diffuse histiocytic lymphoma 78 per cent and for patients with nodular poorly differentiated lymphocytic lymphoma 65 per cent. There were no significant differences in response rates and duration of responses between those on the PEPA program and control patients. The frequency of infection was significantly lower among the patients on the PEPA program, and dosage escalation of the chemotherapeutic agents was accomplished more often among these patients. Dosage escalation did not increase the complete remission rate, but it did reduce the relapse rate and signficantly reduced the fatality rate. The duration of remission and survival was significantly longer for those patients who received dosage escalation.
58例恶性淋巴瘤患者被随机分为两组，30例患者按照保护环境-预防性抗生素（PEPA）方案接受三个疗程的CHOP-Bleo化疗以诱导缓解，另外28例患者作为对照。所有患者的完全缓解率为74%，弥漫性组织细胞淋巴瘤患者为78%，结节性低分化淋巴细胞淋巴瘤患者为65%。接受PEPA方案治疗的患者与对照患者在缓解率和缓解持续时间方面没有显著差异。PEPA方案治疗的患者感染频率显著较低，并且这些患者中更常完成化疗药物的剂量递增。剂量递增并未提高完全缓解率，但确实降低了复发率并显著降低了死亡率。接受剂量递增的患者缓解期和生存期显著更长。
